Ex vivo activation of the GCN2 pathway metabolically reprograms T cells, leading to enhanced adoptive cell therapy

体外激活GCN2通路可对T细胞进行代谢重编程,从而增强过继性细胞疗法。

阅读:6
作者:Michael St Paul ,Samuel D Saibil ,Meghan Kates ,SeongJun Han ,Scott C Lien ,Rob C Laister ,Kebria Hezaveh ,Andreas Kloetgen ,Susanne Penny ,Tingxi Guo ,Carlos Garcia-Batres ,Logan K Smith ,Douglas C Chung ,Alisha R Elford ,Azin Sayad ,Devanand Pinto ,Tak W Mak ,Naoto Hirano ,Tracy McGaha ,Pamela S Ohashi

Abstract

The manipulation of T cell metabolism to enhance anti-tumor activity is an area of active investigation. Here, we report that activating the amino acid starvation response in effector CD8+ T cells ex vivo using the general control non-depressible 2 (GCN2) agonist halofuginone (halo) enhances oxidative metabolism and effector function. Mechanistically, we identified autophagy coupled with the CD98-mTOR axis as key downstream mediators of the phenotype induced by halo treatment. The adoptive transfer of halo-treated CD8+ T cells into tumor-bearing mice led to robust tumor control and curative responses. Halo-treated T cells synergized in vivo with a 4-1BB agonistic antibody to control tumor growth in a mouse model resistant to immunotherapy. Importantly, treatment of human CD8+ T cells with halo resulted in similar metabolic and functional reprogramming. These findings demonstrate that activating the amino acid starvation response with the GCN2 agonist halo can enhance T cell metabolism and anti-tumor activity.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。